Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Futura Medical ( (GB:FUM) ) has issued an update.
Futura Medical plc has announced the details of its upcoming Annual General Meeting (AGM) scheduled for June 19, 2025, and has made its annual report for the year ended December 31, 2024, available on its website. The AGM will be held in London, and shareholders are encouraged to vote via proxy if not attending in person. The announcement underscores Futura’s commitment to transparency and shareholder engagement, while the availability of the annual report provides stakeholders with insights into the company’s financial and operational performance.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £125.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with their lead product Eroxon® being a clinically proven treatment for Erectile Dysfunction (ED). The company has established distribution partnerships in major markets including the US and Europe.
Average Trading Volume: 434,684
Technical Sentiment Signal: Sell
Current Market Cap: £26.89M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.